0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > TIGIT

TIGIT

Brief Information

Name:T cell immunoglobulin and ITIM domains
Target Synonym:V-Set And Immunoglobulin Domain Containing 9,Washington University Cell Adhesion Molecule,V-Set And Transmembrane Domain Containing 3,WUCAM,DKFZp667A205,FLJ39873,V-set and immunoglobulin domain-containing protein 9,TIGIT,VSIG9,T Cell Immunoreceptor With Ig And ITIM Domains,V-Set And Transmembrane Domain-Containing Protein 3,VSIG9, VSTM3,VSTM3,T-Cell Immunoreceptor With Ig And ITIM Domains
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:38
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
TIGIT&PVRIG BsAb - 01 PCC Solid Tumor Solid tumor

Product ListCompare or Buy

Cat . Non Espèces Description du produit Structure Pureté Caractéristique
TIT-HP2H3 Human PE-Labeled Human TIGIT Protein, His TagStar Staining
TIT-HP2H3-structure
TIT-C82E3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, His,Avitag™ (MALS verified)
TIT-C82E3-sds
TIT-M82F3 Mouse Biotinylated Mouse TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-M82F3-structure
TIT-M82F3-sds
TIT-C82F3 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-C82F3-structure
TIT-C82F3-sds
TIT-M82E9 Mouse Biotinylated Mouse TIGIT Protein, His,Avitag™, active dimer (MALS verified)
TIT-M82E9-sds
TIT-H52H5 Human Human TIGIT Protein, His Tag, active dimer (MALS verified)
TIT-H52H5-sds
TIT-H82E6 Human Biotinylated Human TIGIT Protein, His,Avitag™, active dimer (recommended for biopanning) (MALS verified)
TIT-H82E6-sds
TIT-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-C5253-structure
TIT-C5253-sds
TIT-M5253 Mouse Mouse TIGIT Protein, Mouse IgG2a Fc Tag (MALS verified)
TIT-M5253-structure
TIT-M5253-sds
TIT-H82F3 Human Biotinylated Human TIGIT Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
TIT-H82F3-structure
TIT-H82F3-sds
TIT-C52H7 Canine Canine TIGIT Protein, His Tag (MALS verified)
TIT-C52H7-structure
TIT-C52H7-sds
TIT-H5253 Human Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)
TIT-H5253-structure
TIT-H5253-sds
TIT-R5259 Rabbit Rabbit TIGIT Protein, Fc Tag
TIT-R5259-structure
TIT-R5259-sds
TIT-R5258 Rat Rat TIGIT Protein, Fc Tag
TIT-R5258-structure
TIT-R5258-sds
TIT-C5254 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, Fc Tag (MALS verified)
TIT-C5254-structure
TIT-C5254-sds
TIT-C5223 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque TIGIT Protein, His Tag (HPLC verified)
TIT-C5223-structure
TIT-C5223-sds
TIT-C5223-hplc
TIT-H82F1 Human Biotinylated Human TIGIT Protein, Fc,Avitag™ (MALS verified)
TIT-H82F1-structure
TIT-H82F1-sds
TIT-M52E6 Mouse Mouse TIGIT Protein, His Tag (MALS verified)
TIT-M52E6-structure
TIT-M52E6-sds
TIT-M5257 Mouse Mouse TIGIT Protein, Fc Tag (MALS verified)
TIT-M5257-structure
TIT-M5257-sds
TIT-H5254 Human Human TIGIT Protein, Fc Tag (MALS verified)
TIT-H5254-structure
TIT-H5254-sds
ACRO Quality

Part of Bioactivity data

TIT-H5253-Cell-based assay
 TIGIT FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

TIT-H82F1-Cell-based assay
 TIGIT FACS

FACS assay shows Biotinylated Human TIGIT, Fc,Avitag (Cat. No. TIT-H82F1) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT is 0.03 μg/mL (Routinely tested).

TIT-H52H5-SPR
 TIGIT SPR

Anti-hTIGIT antibody captured on CM5 chip via Anti-mouse antibodies surface can bind Human TIGIT, His Tag (Cat. No. TIT-H52H5) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

TIT-C52H7-BLI
 TIGIT BLI

Loaded Human CD155, Fc Tag (Cat. No. CD5-H5251) on Protein A Biosensor, can bind Canine TIGIT, His Tag (Cat. No. TIT-C52H7) with an affinity constant of 5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

TIGIT,VSIG9,VSTM3

Background

TIGIT has been shown to be over expressed on tumor antigen-specific CD8+ T cells and CD8+ tumor infiltrating lymphocytes (TIL). Blockade of TIGIT led to increased cell proliferation, cytokine production, and degranulation of TA-specific CD8+ T cells and TIL CD8+ T cells, which now make it be considered as an immune checkpoint. Recently, studies have shown anti-TIGIT antibody is promising to become a cancer immunotherapy. Our ELISA kit is designed to help the discovery of anti-TIGIT therapeutic antibody.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vibostolimab MK-7684 Phase 3 Clinical Merck Sharp & Dohme Corp Solid tumours; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Domvanalimab AB-154 Phase 3 Clinical Arcus Biosciences Inc Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Melanoma; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lung Neoplasms; Esophageal adenocarcinoma; Cholangiocarcinoma; Biliary Tract Neoplasms; Urinary Bladder Neoplasms; Glioblastoma; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Liver Neoplasms Details
Tiragolumab RO-7092284; MTIG-7192A; RG-6058 Phase 3 Clinical F. Hoffmann-La Roche Ltd Carcinoma, Squamous Cell; Multiple Myeloma; Chordoma; Lymphoma, Follicular; Breast Neoplasms; Sarcoma; Esophageal Squamous Cell Carcinoma; Lymphoma, Non-Hodgkin; Mouth Neoplasms; Carcinoma, Medullary; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Adenocarcinoma; Hemangioendothelioma, Epithelioid; Neoplasm Metastasis; Stomach Neoplasms; Liver Neoplasms; Teratoma; Lymphoma, B-Cell; Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Solid tumours; Esophageal Neoplasms; Rhabdoid Tumor; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms Details
Pembrolizumab/Vibostolimab MK-7684A Phase 3 Clinical Merck & Co Inc Urinary Bladder Neoplasms; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hematologic Neoplasms Details
Rilvegostomig AZD-2936 Phase 3 Clinical Astrazeneca Plc Biliary Tract Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Ociperlimab BGB-A1217 Phase 3 Clinical Beigene Ltd Solid tumours; Biliary Tract Neoplasms; Lymphoma, B-Cell; Esophageal Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms Details
Etigilimab OMP-313M32 Phase 2 Clinical Oncomed Pharmaceuticals Inc Ovarian Neoplasms; Solid tumours; Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Neoplasm Metastasis Details
Renvistobart BMS-986207 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ZG-005 ZG-005 Phase 2 Clinical Gensun Biopharma Inc Solid tumours; Neoplasms; Carcinoma, Neuroendocrine; Uterine Cervical Neoplasms Details
HB-0036 HB-0036 Phase 2 Clinical Solid tumours; Carcinoma, Non-Small-Cell Lung Details
AGEN-1777 AGEN-1777; BMS-986442 Phase 2 Clinical Agenus Inc Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
PM-1022 PM-1022 Phase 2 Clinical Biotheus Inc Neoplasms Details
Lancastotug AK-127 Phase 2 Clinical Zhongshan Akeso Biopharma Co Ltd Solid tumours; Neoplasms; Carcinoma, Hepatocellular Details
Belrestotug EOS-448; EOS-884448; GSK-4428859; GSK-4428859A Phase 2 Clinical Iteos Head and Neck Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Multiple Myeloma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
HLX-53 HLX-53; HLX53 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
HL-301 HL-301 Phase 2 Clinical Hanlim Pharm Co Ltd Radiation Pneumonitis; Small Cell Lung Carcinoma; Lung Neoplasms Details
JS-006 JS-006; TAB-006; CHS-006 Phase 2 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours; Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Dargistotug M-6223; M6223 Phase 2 Clinical Emd Serono Research & Development Institute Inc Solid tumours; Carcinoma, Transitional Cell; Neoplasm Metastasis Details
DW-2008 DW-2008; DW-2008S Phase 1 Clinical Dong Wha Pharm Co Ltd Coronavirus Disease 2019 (COVID-19); Rhinitis, Allergic; Asthma Details
Tamgiblimab IBI-939 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Neoplasms; Lung Neoplasms Details
COM-902 COM-902 Phase 1 Clinical Compugen Ltd Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Neoplasms; Colonic Neoplasms; Multiple Myeloma; Neoplasms, Plasma Cell; Colorectal Neoplasms; Lung Neoplasms Details
AK-130 AK-130 Phase 1 Clinical Zhongshan Akeso Biopharma Co Ltd Neoplasms; Carcinoma, Hepatocellular Details
SIM-0348 SIM-0348 Phase 1 Clinical Simcere Pharmaceutical Group Ltd Solid tumours; Neoplasms Details
Recombinant humanized anti-TIGIT monoclonal antibody(Lepu biopharma) LP-010 Phase 1 Clinical Solid tumours Details
ASP-8374 ASP-8374; PTZ-201 Phase 1 Clinical Potenza Therapeutics, Astellas Pharma Inc Solid tumours; Glioblastoma Details
ZGGS-15 ZGGS15; ZGGS-15 Phase 1 Clinical Suzhou Zelgen Biopharmaceuticals Co Ltd Solid tumours Details
AUR-106 AUR-106 Phase 1 Clinical Aurigene Discovery Technologies Ltd Kidney Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Colonic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
BC008-1A BC008-1A Phase 1 Clinical Sichuan Luzhou Buchang Biopharmaceutical Co Ltd Solid tumours Details
SHR-2002 SHR-2002 Phase 1 Clinical Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Neoplasms Details
PM-1021 PM1021 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms Details
SHS-006(Nanjing Sanhome Pharmaceutical) SHS-006; SH-006; SH006 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Solid tumours Details
HB0030 HB-0030 Phase 1 Clinical Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
BAT-6005 BAT-6005 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours Details
IBI-321 IBI-321 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Neoplasms Details
Ralzapastotug AB-308 Phase 1 Clinical Arcus Biosciences Inc Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Adenocarcinoma Details
PM-1009 PM1009 Phase 1 Clinical Biotheus Inc Solid tumours; Neoplasms; Lung Neoplasms Details

This web search service is supported by Google Inc.

totop

Laisser un message